24 December 2024
Mendell Helium
plc
("Mendell
Helium" or the "Company")
Unaudited Interim Results for
the six months ended 30 September 2024
The unaudited interim results of
Mendell Helium plc for the six months ended 30 September 2024 are
presented below. As announced on 14 October 2024, the trading
operations to which these results relate, namely the Voyager and
Amphora-branded plant based health & wellness business, have
since been sold to Orsus Therapeutics plc ("Orsus"), a private
label turnkey solutions provider specialising in developing,
formulating, marketing & sales of health and wellness products
for global brands.
Highlights:
·
Mendell Helium owns approximately 28% of Orsus
with further upside potential based on the achievement of revenue
targets
·
Mendell Helium has no further obligation to
contribute to the running costs of the plant based health &
wellness business with effect from 1 October 2024
·
Fundraising completed in June 2024 to begin the
Company's development as a helium producer in Kansas,
USA
Post period operational
highlights
As
announced on 27 June 2024, the Company has an option to
acquire M3 Helium ("M3 Helium Corp."), a producer of helium which
is based in Kansas and holds an interest in nine
wells. There is no certainty that the Company's option
to acquire M3 Helium will be exercised, nor that the enlarged group
will successfully complete its re-admission to trading on the AQSE
Growth Market.
Since the option was granted, M3
Helium's business has undergone some significant but positive
developments:
·
It has signed a farm in agreement with Scout
Energy Partners ("Scout Energy")
over 161,280 acres
of the Hugoton gas field, one of the largest natural
gas fields in North America
·
The Nilson well, which at a production of 127
Mcf/day and being within the top 1% of Hugoton wells, has proved a
new strategy for production in that gas field
·
The Rost well at Fort Dodge, with a 5.1%
helium content, has shown potential to be a far higher producer
than originally envisaged, capable of covering all of the Company's overheads
·
M3 Helium has acquired two further producing wells
(Bearman, Demmit) on the western side of the Hugoton gas
field in Stanton County, Kansas
·
Preliminary indications of funding interest
received from local oil & gas companies and deferred payment
terms have been offered by fracking contractor
·
Admission document to finalise the acquisition of
M3 Helium expected to be published in Q1 2025
This announcement contains inside
information for the purposes of UK Market Abuse Regulation and
has been arranged for release by Eric Boyle,
Chairman. The Directors of the Company accept
responsibility for the content of this announcement.
Enquiries:
Mendell Helium plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
nick@mendellhelium.com
https://mendellhelium.com/
|
Cairn Financial Advisers LLP (AQSE Corporate
Adviser)
Ludovico Lazzaretti/Liam
Murray
|
Tel: +44 (0) 20 7213 0880
|
SI
Capital Limited (Broker)
Nick Emerson
|
Tel: +44 (0) 1483 413500
|
Stanford Capital Partners Ltd (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
Brand Communications (Public & Investor
Relations)
Alan Green
|
Tel: +44 (0) 7976 431608
|
Overview of M3 Helium
Mendell Helium plc, formerly Voyager
Life plc, announced on 27 June 2024 that it has entered into an
option agreement to acquire the entire issued share capital of M3
Helium Corp. through the issue of 57,611,552 new ordinary shares in
Mendell Helium to M3 Helium's shareholders. The exercise of
the option will constitute a reverse takeover pursuant to AQSE Rule
3.6 of the Access Rule Book and is subject to, inter alia, publication of an admission
document.
M3 Helium has interests in nine
wells in South-Western Kansas of which five (Peyton, Smith, Nilson,
Bearman and Demmit) are in production. Eight of the company's
wells are within the Hugoton gas field, one of the largest natural
gas fields in North America. Significantly these wells are in
the proximity of a gathering network and the Scout Energy Partners
("Scout Energy") Jayhawk gas processing plant meaning that
producing wells can quickly be tied into the
infrastructure.
The nineth well, Rost, is in Fort
Dodge, Kansas and was tested in July 2024 as containing 5.1% helium composition. Although not
within direct access to the gathering network, M3 Helium owns a
mobile Pressure Swing Adsorption production plant which could be
used to purify the helium on site.
Chairman's Statement
I am pleased to present Mendell
Helium's interim results for the six-month period to 30 September
2024.
Post period end, on 14 October
2024 we entered into a share purchase
agreement to dispose of our plant based health and wellness
business to Orsus (the "Disposal").
The Disposal was subsequently approved by shareholders in
a general meeting on 11 November 2024 and completed on the same
day.
Pursuant to the Disposal, Orsus
acquired our three wholly owned subsidiaries, being VoyagerCann
Limited, Amphora Health Limited and Voyager Life Limited, which,
combined, own all of the Company's plant based health and wellness
business. It was a term of the Disposal that Orsus took
responsibility for all running costs of this business with effect
from 1 October 2024. Consequently, the results we are
presenting today are not indicative of Mendell Helium's likely
future trading.
We do however remain keenly
interested in the ongoing success of the Voyager-named operations
as the consideration that we received for
the Disposal was new ordinary shares in Orsus,
representing approximately 28% of the enlarged Orsus group, and
warrants in Orsus, exercisable on the achievement of certain
revenue hurdles by the businesses we sold. If exercised,
those warrants represent a further 16% of the enlarged Orsus
group's share capital on a fully diluted basis.
Turning now to the future, on 27
June 2024 we announced a
fundraising of £864,468 through the issue of new ordinary
shares at an issue price of 3 pence per share. At
the same time, we entered into an option agreement (the "Option")
to acquire M3 Helium and have since concentrated our time and
effort on developing its operations.
Since the Option was granted, M3
Helium's business has undergone some significant but positive
developments:
·
It has signed a farm in agreement with Scout
Energy over 161,280 acres of the Hugoton gas field,
one of the largest natural gas fields in North
America
·
The Nilson well, which at a production of 127
Mcf/day and being within the top 1% of Hugoton wells, has proved a
new strategy for production in that gas field
·
The Rost well at Fort Dodge, with a 5.1%
helium content, has shown potential to be a far higher producer
than originally envisaged, capable of covering all of the Company's overheads
·
M3 Helium has acquired two further producing wells
(Bearman, Demmit) on the western side of the Hugoton gas
field in Stanton County, Kansas
·
Preliminary indications of funding interest
received from local oil & gas companies and deferred payment
terms have been offered by fracking contractor
To further these initiatives, the
Company has extended a loan of US$510,000 to M3 Helium and Nick
Tulloch, our CEO, has been appointed as chairman of M3 Helium,
bringing the two companies even closer together ahead of the
proposed merger.
Outlook
As we head into 2025, we have plenty
to look forward to. We expect to publish our admission
document in connection with the exercise of the Option in Q1
2025. We are aiming to bring Rost into production at around
the same time and then turn our attention to developing the acreage
in the Hugoton in line with M3 Helium's agreement with Scout
Energy.
Key to M3 Helium's farm in
agreement with Scout Energy is the Nilson well
where production continues to steadily rise. M3 Helium is now
delivering 127 Mcf/day of gas into Scout Energy's gathering system
for processing at the Jayhawk plant. At these levels, Nilson
is within the top 1% producing wells in the Hugoton. At
the current rate of 127 Mcf/day, Nilson is producing over 20 Mcf of
helium each month (based on a helium composition of 0.6%).
This equates to a monthly revenue of
approximately $10,000 (revenue including helium and
natural gas liquids).
M3 Helium's ability to repeat
further Nilson-type wells within the acreage it has farmed into is
what the M3 Helium management team believe, can make the agreement
with Scout Energy a significant success.
In the nearer term, production at
Rost is expected to cover a large part of the Company's overheads,
meaning that all new funding would be fully directed towards its
plans in the Hugoton. The cost of bringing Rost into
production is estimated at US$400,000. This comprises
the disposal well, a bigger pump, a compressor for injecting gas
into tube trailers for transport and integrating the Pressure-Swing
Adsorption modular processing unit to enable purification of helium
onsite. These works are estimated to take up to two months
from commencement.
However, very encouragingly, M3
Helium's team have identified potential cost and time savings by
examining a nearby unused well and believe that there is a
zone at around 4,000 feet depth that could take water. If that
solution works, then M3 Helium would not need to drill out the
bottom plugs, buy casing or cement. Net savings from proceeding
along this route, if successful, would amount to
over US$100,000. We will know whether this plan is
viable once works commence in the new year.
M3 Helium is one of very few
companies that is able to claim helium production. This very
valuable gas, with no known substitute, has understandably driven
plenty of commercial and investor attention in recent years.
Finding it may be the first step but bringing it to surface and
getting it to market is ultimately what counts. M3 Helium has
a guaranteed offtake from Scout Energy, access to nearby
infrastructure and a development opportunity over one of the prime
sources of helium in the world. M3 Helium's successes in the
US, particularly with the Nilson well, are generating considerable
attention and we are confident that UK investors will shortly be
able to see the opportunity that we have created.
Our latest investor presentation is
available to download at
https://mendellhelium.com/reports/.
Eric Boyle
Chairman
24 December 2024
Financial Review of the six months ended 30 September
2024
During the period under review
Mendell Helium operated primarily as a health and wellness company
manufacturing, supplying and retailing high-quality plant-based
health and wellness products with a particular focus on
Cannabidiol (CBD), hemp seed oil and hemp-related
products.
The Company was incorporated on 12
November 2020 and, on 30 June 2021, trading
in its ordinary shares commenced on the Aquis Stock Exchange Growth
Market. The comparatives reflect the equivalent period from
last year and for the year ended 31 March 2024.
The Company achieved sales in the
six-month period to 30 September 2023 of £169,000, an increase of 2
per cent. over the same period last year. Gross margins
however improved to 43 per cent. (2023: 39 per cent.) reflecting
cost controls that were implemented and which more than offset
rising raw materials costs.
Likewise, despite inflationary
pressures and rising employment costs, administrative expenses were
down by almost only 3 per cent. from the same period last
year.
The Company made a loss after tax
for the period of £470,000.
Following on from its R&D award
last year, the Company successfully applied for and was awarded an
R&D tax credit of £36,000 for the financial year ending 31
March 2023.
Unaudited Consolidated Statement of
Comprehensive Income
for the six months ended 30 September
2024
|
6 months to
30 September
2024
£'000
|
6 months
to
30
September 2023
£'000
|
Year
ended
31 March
2024
£'000
|
|
|
|
|
Revenue
|
169
|
165
|
304
|
Cost of sales
|
(96)
|
(100)
|
(178)
|
Gross profit
|
73
|
65
|
126
|
|
|
|
|
Administrative expenses
|
(570)
|
(586)
|
(1,217)
|
Other operating income
|
-
|
2
|
2
|
Operating loss
|
(497)
|
(519)
|
(1,089)
|
|
|
|
|
Net finance expense
|
(9)
|
(9)
|
(15)
|
IPO associated costs
|
-
|
-
|
-
|
Loss
before tax
|
(506)
|
(528)
|
(1,104)
|
|
|
|
|
Taxation
|
36
|
27
|
27
|
Loss
after tax
|
(470)
|
(501)
|
(1,077)
|
|
|
|
|
Earnings per share
|
(1.79p)
|
(3.58p)
|
(8.2p)
|
There was no other comprehensive
income in the period. All activities relate to continuing
operations.
Unaudited Consolidated Statement of
Financial Position
at 30 September 2024
|
As at
30 September
2024
£'000
|
As at
30
September 2023
£'000
|
As at
31
March
2024
£'000
|
Non-current assets
|
|
|
|
Intangible assets
|
43
|
1
|
44
|
Tangible assets
|
18
|
46
|
34
|
Right-of-use assets
|
490
|
542
|
534
|
Trade and other receivables: falling
due after one year
|
18
|
17
|
18
|
Total non-current assets
|
569
|
606
|
630
|
|
|
|
|
Current assets
|
|
|
|
Inventory
|
95
|
101
|
117
|
Trade and other receivables: falling
due within one year
|
472
|
128
|
19
|
Cash and cash equivalents
|
160
|
551
|
163
|
Total current assets
|
727
|
780
|
299
|
|
|
|
|
Total assets
|
1,296
|
1,386
|
929
|
|
|
|
|
Current liabilities
|
|
|
|
Trade and other payables < 1
year
|
(289)
|
(240)
|
(285)
|
|
|
|
|
Non-current liabilities
|
|
|
|
Lease liabilities > 1
year
|
(472)
|
(530)
|
(504)
|
|
|
|
|
Total liabilities
|
(761)
|
(770)
|
(789)
|
|
|
|
|
Total net assets
|
535
|
616
|
140
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Company
|
|
|
|
Share capital
|
432
|
140
|
144
|
Share premium
|
2,626
|
2,004
|
2,049
|
Share based payments
reserve
|
186
|
135
|
186
|
Retained earnings
|
(2,709)
|
(1,663)
|
(2,239)
|
|
|
|
|
Total Equity
|
535
|
616
|
140
|
Unaudited Consolidated Cash Flow Statement
for the six months ended 30 September
2024
|
|
6 months to
30 September
2024
£'000
|
6 months
to
30
September 2023
£'000
|
Year
ended
31
March
2024
£'000
|
Cash
flows from operating activities
|
|
|
|
|
|
|
|
|
|
Loss before tax
|
|
(506)
|
(528)
|
(1,104)
|
Adjustments for:
|
|
|
|
|
Depreciation of fixtures, fittings
and equipment
|
|
12
|
13
|
27
|
Depreciation of right-of-use
assets
|
|
44
|
42
|
87
|
(Profit) on disposal of fixtures,
fittings and equipment
|
|
(7)
|
-
|
-
|
Finance expense - interest on lease
liabilities
|
|
10
|
11
|
21
|
Finance income
|
|
(1)
|
|
40
|
Tax Received
|
|
36
|
27
|
27
|
Share based remuneration
|
|
-
|
-
|
51
|
|
|
(412)
|
(435)
|
(851)
|
|
|
|
|
|
Increase in trade and other
receivables
|
|
(453)
|
(48)
|
59
|
Increase in trade and other
payables
|
|
4
|
63
|
88
|
Decrease in inventories
|
|
22
|
24
|
25
|
Cash
used in operations
|
|
(839)
|
(396)
|
(679)
|
|
|
|
|
|
Investing activities
|
|
|
|
|
Purchase of tangible fixed
assets
|
|
(1)
|
(3)
|
(5)
|
Purchase of Intangible
Assets
|
|
-
|
-
|
-
|
Acquisition of Right of Use
Assets
Escrow Account
|
|
-
-
|
-
500
|
-
460
|
Net
cash used in investing activities
|
|
(1)
|
497
|
455
|
|
|
|
|
|
|
|
|
|
|
Financing activities
|
|
|
|
|
Repayment of lease
liabilities
|
|
(41)
|
(40)
|
(103)
|
Disposal of fixtures, fittings and
equipment
|
|
13
|
-
|
-
|
Proceeds from issue of shares, net of
issue costs
|
|
865
|
-
|
-
|
|
|
|
|
|
Net
cash generated from financing activities
|
|
837
|
(40)
|
(103)
|
|
|
|
|
|
|
|
|
|
|
Net
increase in cash and cash equivalents
|
|
(3)
|
61
|
(327)
|
Cash and cash equivalents at
beginning of period
|
|
163
|
490
|
490
|
Exchange rate differences on cash and
cash equivalents
|
|
|
|
|
Cash
and cash equivalents at end of period
|
|
160
|
551
|
163
|
|
|
|
|
|
Unaudited Consolidated Statement of Changes in
Equity
for the six months ended 30
September 2024
|
|
Share
capital
|
|
Share
Premium
|
|
Share based Payments
Reserve
|
|
Retained
earnings
|
|
Total
equity
|
|
|
£'000
|
|
£'000
|
|
£'000
|
|
£'000
|
|
£'000
|
Balance 1 April 2023
|
|
140
|
|
2,004
|
|
135
|
|
(1,162)
|
|
1,117
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period
|
|
-
|
|
-
|
|
-
|
|
(1,077)
|
|
(1,077)
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
140
|
|
2,004
|
|
135
|
|
(2,239)
|
|
40
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
|
Issue of shares
|
|
4
|
|
45
|
|
-
|
|
-
|
|
49
|
Share issue costs
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
Reserves transfer
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
Shares based remuneration
|
|
-
|
|
-
|
|
51
|
|
-
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
At
31 March 2024
|
|
144
|
|
2,049
|
|
186
|
|
(2,239)
|
|
140
|
|
|
Share
capital
|
|
Share
Premium
|
|
Share based Payments
Reserve
|
|
Retained
earnings
|
|
Total
equity
|
|
|
£'000
|
|
£'000
|
|
£'000
|
|
£'000
|
|
£'000
|
Balance at 1 April 2024
|
|
144
|
|
2,049
|
|
186
|
|
(2,239)
|
|
140
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period
|
|
-
|
|
-
|
|
-
|
|
(470)
|
|
(470)
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
144
|
|
2,049
|
|
186
|
|
(2,709)
|
|
(330)
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
|
Issue of shares
|
|
288
|
|
577
|
|
-
|
|
-
|
|
865
|
Share issue costs
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
Reserves transfer
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
Shares based remuneration
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
At
30 September 2024
|
|
432
|
|
2,626
|
|
186
|
|
(2,709)
|
|
535
|
The following describes the nature
and purpose of each reserve within equity:
Reserve
|
Description and purpose
|
Share capital
|
Amount subscribed for share capital
at the nominal value of £0.01 per ordinary share
|
Share premium
|
Amount subscribed for share capital
in excess of nominal value, net of share issue costs
|
Shares to be issued
|
Amounts received in respect of shares
to be issued
|
Equity reserve
|
Amounts recognised for share-based
payment transactions including share options granted to employees
and other parties
|
Retained earnings
|
Cumulative net gains and losses
recognised in the consolidated statement of comprehensive
income
|
Notes to the Interim
Results
for the six months ended 30
September 2024
1. Basis of preparation
This announcement has been prepared
in accordance with International Financial Reporting Standards,
International Accounting Standards and Interpretations
(collectively IFRS) issued by the International Accounting
Standards Board (IASB) as adopted by the European Union ("adopted
IFRS"), and with the Companies Act 2006 applicable to companies
reporting under IFRS.
Going
concern
The financial statements have been
prepared on a going concern basis. In assessing whether the going
concern assumption is appropriate, the Directors take into account
all available information for the foreseeable future, in particular
for the twelve months from the date of approval of the financial
statements. This information includes management prepared cash
flows forecasts, available sources of funding and consideration of
how the global economic downturn may impact product launches and
sales.
The Directors have a reasonable
expectation that the Company has adequate resources to continue in
operational existence for the foreseeable future. Thus, they
continue to adopt the going concern basis of accounting in
preparing the financial statements.
2. Profit/(loss) per share
Basic earnings per share is
calculated by dividing the profit attributable to equity holders of
the Company by the weighted average number of ordinary shares in
issue during the year, excluding ordinary shares purchased by the
Company and held as treasury shares.
The number of ordinary shares of 1
pence each used in the calculation of earnings per
share:
|
6 months to
30 September
2024
|
6 months
to
30
September 2023
|
Year
ended
31 March
2024
|
Weighted average number of ordinary
shares in issue
|
26,212,563
|
13,986,244
|
13,059,359
|
3. Segmental information
Revenue
All revenue arises from the retail
of products for the health and wellness market as
follows:
|
6 months to
30 September
2024
£'000
|
6 months
to
30
September 2023
£'000
|
Year
ended
31
March
2024
£'000
|
Revenue
|
|
|
|
Trade customers
|
77
|
62
|
142
|
Voyager stores
|
66
|
82
|
125
|
Online sales and trade fairs
|
26
|
21
|
37
|
|
|
|
|
Total
|
169
|
165
|
304
|
|
|
|
|
4. Forward-looking statements
These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not a guarantee of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
5. Other information
The financial information in this
report does not constitute statutory accounts within the meaning of
section 434 of the Companies Act 2006.
The interim results for the six
months ended 30 September 2024 are unaudited. The interim financial
statements have been prepared using accounting policies consistent
with International Financial Reporting Standards (IFRS) and
International Financial Reporting Interpretations Committee (IFRIC)
interpretations as endorsed by the European Union. The same
accounting policies, presentation and methods of computation have
been followed in the preparation of these results as were applied
in the Company's audited financial statements dated 31 March 2024,
as presented for the purpose of the Admission
Document.